Shoulder Innovations (NYSE:SI) Given “Overweight” Rating at Piper Sandler

Piper Sandler reaffirmed their overweight rating on shares of Shoulder Innovations (NYSE:SI) in a report issued on Friday morning,Benzinga reports. The firm currently has a $25.00 price target on the stock, up from their prior price target of $19.00.

A number of other analysts have also recently issued reports on SI. BTIG Research raised their target price on shares of Shoulder Innovations from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday. UBS Group started coverage on shares of Shoulder Innovations in a research report on Tuesday, July 28th. They set a “buy” rating and a $27.00 price target on the stock. Finally, Weiss Ratings raised shares of Shoulder Innovations from a “sell (d-)” rating to a “sell (d)” rating in a report on Monday. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $23.33.

Shoulder Innovations Stock Performance

Shares of SI stock opened at $20.54 on Friday. The company has a quick ratio of 10.04, a current ratio of 11.81 and a debt-to-equity ratio of 0.11. The company’s fifty day simple moving average is $19.91 and its 200-day simple moving average is $16.07. The firm has a market cap of $426.06 million and a PE ratio of -10.70. Shoulder Innovations has a 12 month low of $10.92 and a 12 month high of $24.59.

Shoulder Innovations (NYSE:SI) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.03. The firm had revenue of $16.71 million during the quarter. Shoulder Innovations had a negative return on equity of 22.93% and a negative net margin of 58.33%. Equities research analysts expect that Shoulder Innovations will post -1.67 EPS for the current fiscal year.

Insider Buying and Selling at Shoulder Innovations

In related news, major shareholder Healthcare Holding B.V. Gilde sold 2,095 shares of the firm’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $22.60, for a total value of $47,347.00. Following the transaction, the insider owned 2,212,207 shares in the company, valued at approximately $49,995,878.20. This trade represents a 0.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Matthew Fraser Ahearn sold 4,144 shares of the company’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $18.84, for a total transaction of $78,072.96. Following the sale, the chief operating officer directly owned 269,176 shares of the company’s stock, valued at $5,071,275.84. This represents a 1.52% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 188,275 shares of company stock worth $4,219,793. 29.00% of the stock is currently owned by insiders.

Institutional Trading of Shoulder Innovations

Large investors have recently made changes to their positions in the company. Roubaix Capital LLC lifted its stake in Shoulder Innovations by 61.9% during the first quarter. Roubaix Capital LLC now owns 257,121 shares of the company’s stock worth $3,736,000 after purchasing an additional 98,305 shares during the last quarter. Sectoral Asset Management Inc. increased its stake in shares of Shoulder Innovations by 14.4% in the 4th quarter. Sectoral Asset Management Inc. now owns 492,435 shares of the company’s stock valued at $7,042,000 after purchasing an additional 62,153 shares during the last quarter. KCM Capital Inc bought a new position in shares of Shoulder Innovations in the 1st quarter valued at $509,000. Royal Bank of Canada raised its holdings in shares of Shoulder Innovations by 7,046.3% during the 1st quarter. Royal Bank of Canada now owns 53,883 shares of the company’s stock worth $783,000 after buying an additional 53,129 shares in the last quarter. Finally, Wells Fargo & Company MN lifted its position in shares of Shoulder Innovations by 66.3% during the 4th quarter. Wells Fargo & Company MN now owns 5,250 shares of the company’s stock worth $75,000 after buying an additional 2,094 shares during the last quarter.

Shoulder Innovations News Roundup

Here are the key news stories impacting Shoulder Innovations this week:

• Positive Sentiment: Analysts raised their targets: Piper Sandler reaffirmed its “overweight” rating and lifted its price target from $19 to $25, while BTIG Research raised its target from $24 to $26 and initiated a “buy” rating. These targets imply meaningful upside and may support investor sentiment. Benzinga analyst rating updates
• Positive Sentiment: Revenue growth remained strong: Second-quarter revenue increased approximately 56% year over year to $17.2 million, slightly exceeding estimates. Gross profit rose about 60%, indicating continued demand and improving product economics. Shoulder Innovations Q2 2026 earnings summary
• Positive Sentiment: Full-year guidance was raised: SI forecast fiscal-year revenue of $67 million to $69 million, broadly in line with the roughly $67.1 million consensus estimate. Management also highlighted 60% first-half revenue growth. Shoulder Innovations raises full-year outlook
• Neutral Sentiment: Liquidity appears adequate but is declining: The company ended the quarter with $24.5 million in cash and used $7.4 million in operating activities and $2.2 million in capital expenditures. Investors will likely monitor whether revenue growth can lead to improved cash generation.
• Negative Sentiment: Profitability remains a concern: SI reported an operating loss of about $10 million, a net loss of approximately $10.2 million, and diluted EPS near negative $0.49, missing some estimates. The company remains deeply unprofitable, increasing valuation sensitivity. Shoulder Innovations quarterly results
• Negative Sentiment: Major-holder selling may weigh on sentiment: Gilde Healthcare sold more than 110,000 shares in early August for roughly $2.5 million. Although it retains a substantial stake, the sales can raise concerns about near-term supply and insider conviction. Gilde Healthcare insider sale

About Shoulder Innovations

Shoulder Innovations (NYSE:SI) is a medical device company focused on the design, development and commercialization of shoulder implant systems and related surgical instruments for orthopedic surgery. The company’s product portfolio includes modular shoulder prostheses, humeral and glenoid components, and instrumentation kits designed to facilitate both primary and revision shoulder arthroplasty procedures. Emphasizing a patient-centric approach, Shoulder Innovations works to offer implant solutions that aim to restore mobility and reduce post-operative complications.

In addition to its core implant offerings, Shoulder Innovations provides comprehensive clinical support and training programs for surgeons and operating room teams.